Wednesday, 8 September 2010

08.09.2010

Initial data-analysis concerning the elevated number of narcolepsy cases in Sweden and Finland in 2010 has not shown a skew toward children who were given GlaxoSmithKline vaccine Pandemrix. The studies into the matter and to potential different reason behind the issue continue.

Novo Nordisk has sold its 26% ownership in Zymogenetics to Bristol-Meyers Squibb. Novo Nordisk marks an accounting profit of 1.1 billion Danish kroner on the sale. Karo Bio plunged nearly 10% on the news that Merck is discontinuing development of MK-6913 for hot flashes.

Should the Obama infrastructure stimulus pass, Swedish companies like Hexagon, Volvo and Skanska may stand to reap big profits, writes Dagens Industri. Swedish chain store Clas Ohlson AB’s Q2 result came in at 115 million Kronor. Swedish government is knocking on Saab’s door for a 12 million Euro payment within two weeks.

Sweden’s GDP jumped 4,6% and Finland’s GDB grew at 3,7% clip in Q2 2010 compared to 2009. Greek Q2 numbers were revised downward but a successful Portuguese bond auction and upwardly revised GDP number from there gave a tailwind to markets.

No comments:

Post a Comment